Antiviral Activities of Oral 1-O-Hexadecylpropanediol-3-Phosphoacyclovir and Acyclovir in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection
- 1 July 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (7) , 1964-1969
- https://doi.org/10.1128/aac.44.7.1964-1969.2000
Abstract
Acyclovir triphosphate is a potent inhibitor of hepatitis B virus DNA polymerase, but acyclovir treatment provides no benefit in patients with hepatitis B virus infection. This is due in part to the fact that hepatitis B virus, unlike herpes simplex virus, does not code for a viral thymidine kinase which catalyzes the initial phosphorylation of acyclovir. We synthesized 1-O-octadecyl-sn-glycero-3-phospho (3-P)-acyclovir and found that it was highly active in reducing hepatitis B virus replication in 2.2.15 cells, while acyclovir was inactive. The greater antiviral activity of 1-O-octadecyl-sn-glycero-3-P-acyclovir appeared to be due to liver cell metabolism of the compound to acyclovir monophosphate (K. Y. Hostetler et al., Biochem. Pharmacol. 53:1815–1822, 1997). However, a closely related compound without a hydroxyl group at thesn-2 position of glycerol, 1-O-hexadecylpropanediol-3-P-acyclovir, was more active and selective in 2.2.15 cells in vitro. In this study, we treated woodchucks chronically infected with woodchuck hepatitis virus with increasing oral doses of 1-O-hexadecylpropanediol-3-P-acyclovir and assessed the response to therapy versus acyclovir or a placebo. At a dosage of 10 mg/kg of body weight twice a day, the test compound significantly inhibited viral replication in vivo, as indicated by a 95% reduction in serum woodchuck hepatitis virus DNA levels and by a 54% reduction in levels of woodchuck hepatitis virus replicative intermediates in the liver. Higher doses were somewhat less effective. In contrast, 20 mg of acyclovir/kg twice daily, a 5.3-fold-higher molar dosage, had no demonstrable activity against woodchuck hepatitis virus. Oral 1-O-hexadecylpropanediol-3-P-acyclovir appeared to be safe and effective in chronic woodchuck hepatitis virus infection.Keywords
This publication has 37 references indexed in Scilit:
- Liver-targeted antiviral nucleosides: Enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivoHepatology, 1996
- Acyclic Guanosine Analogs Inhibit DNA Polymerases .alpha., .delta., and .epsilon. with Very Different Potencies and Have Unique Mechanisms of ActionBiochemistry, 1995
- Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trialHepatology, 1993
- Interferon-α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo-controlled trialHepatology, 1993
- Zidovudine inhibits hepatitis B virus replicationAntiviral Research, 1992
- Failure of acyclovir to enhance the antiviral effect of α lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis BJournal of Hepatology, 1992
- No effect of zidovudine on hepatitis B virus replication in homosexual men with symptomatic HIV-1 infectionAIDS, 1991
- A controlled trial of acyclovir in stable chronic HBsAg, HBeAg-positive carriersJournal of Hepatology, 1986
- Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2′-deoxy-2′-fluoro-β-d-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2′-deoxyuridineAntiviral Research, 1984
- Absorption and metabolism of lecithin and lysolecithin by intestinal slicesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1967